Side-by-side · Research reference

AdipotidevsPinealon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BHuman-MechanisticAUTO-DRAFTED12/36 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

01Mechanism of Action

Parameter

Adipotide

Pinealon

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

—

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

Pinealon

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

—

Frequency

Not specified in available data

Once daily during cycle

Evidence basis

Preclinical animal models only

Russian clinical trials + in vitroKhavinson 2014

Human data

None — no clinical trials reported

—

Standard dose

—

5–10 mg / day for 10 daysKhavinson 2014

Lower / starter dose

—

2.5 mg / day

Duration

—

10-day cycles, 1–2× per year

Reconstitution

—

Bacteriostatic water

Timing

—

No specific time

Half-life

—

Hours

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Pinealon

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

Pinealon

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Injection site reaction

—

Mild irritation

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Pinealon

·Pregnancy / breastfeeding

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Pinealon

·Active malignancy (theoretical via gene expression modulation)

05Administration Protocol

Parameter

Adipotide

Pinealon

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Add 1–2 mL bacteriostatic water to 10 mg vial.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

SQ — abdomen preferred.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Daily during cycle, any time.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Adipotide

— no documented stacks

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003